{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:25:25Z","timestamp":1791404725267,"version":"4.3.3"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1038\/nm1221","type":"journal-article","created":{"date-parts":[[2005,4,6]],"date-time":"2005-04-06T13:21:32Z","timestamp":1112793692000},"page":"S33-S44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis"],"prefix":"10.1038","volume":"11","author":[{"given":"Stefan H E","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"McMichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,4,5]]},"reference":[{"key":"BFnm1221_CR1","unstructured":"World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing (World Health Organization, Geneva, 2004)."},{"key":"BFnm1221_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/79631","volume":"6","author":"SHE Kaufmann","year":"2000","unstructured":"Kaufmann, S.H.E. Is the development of a new tuberculosis vaccine possible? Nat. Med. 6, 955\u2013960 (2000).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR3","volume-title":"Die Schutzimpfung gegen Tuberkulose mit \u201cBCG\u201d","author":"A Calmette","year":"1928","unstructured":"Calmette, A. Die Schutzimpfung gegen Tuberkulose mit \u201cBCG\u201d (F.C.W. Vogel, Leipzig, 1928)."},{"key":"BFnm1221_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/35035103","volume":"407","author":"ES Rosenberg","year":"2000","unstructured":"Rosenberg, E.S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523\u2013526 (2000).","journal-title":"Nature"},{"key":"BFnm1221_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00001","volume":"137","author":"M Dybul","year":"2002","unstructured":"Dybul, M., Fauci, A.S., Bartlett, J.G., Kaplan, J.E. & Pau, A.K. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137, 381\u2013433 (2002).","journal-title":"Ann. Intern. Med."},{"key":"BFnm1221_CR6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/01.qai.0000127062.94627.31","volume":"37","author":"RG White","year":"2004","unstructured":"White, R.G. et al. Can Population Differences Explain the Contrasting Results of the Mwanza, Rakai, and Masaka HIV\/Sexually Transmitted Disease Intervention Trials?: A Modeling Study. J. Acquir. Immune Defic. Syndr. 37, 1500\u20131513 (2004).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnm1221_CR7","first-page":"287","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"L Kremer","year":"2005","unstructured":"Kremer, L. & Besra, G.S. A waxy tale by Mycobacterium tuberculosis. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 287\u2013305 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR8","first-page":"437","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"J Chan","year":"2005","unstructured":"Chan, J., Silver, R.F., Kampmann, B. & Wallis, R.S. Intracelluar models of Mycobacterium tuberculosis infection. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 437\u2013449 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR9","first-page":"427","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"DG Russell","year":"2005","unstructured":"Russell, D.G. Mycobacterium tuberculosis: the indigestible microbe. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 427\u2013435 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR10","first-page":"465","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"SHE Kaufmann","year":"2005","unstructured":"Kaufmann, S.H.E. & Flynn, J.L. CD8 T cells in tuberculosis. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 465\u2013474 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR11","first-page":"475","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"CC Dascher","year":"2005","unstructured":"Dascher, C.C. & Brenner, M.B. CD1 and tuberculosis. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 475\u2013487 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR12","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1073\/pnas.93.6.2272","volume":"93","author":"SHE Kaufmann","year":"1996","unstructured":"Kaufmann, S.H.E. gamma\/delta and other unconventional T lymphocytes: What do they see and what do they do? Proc. Natl. Acad. Sci. USA 93, 2272\u20132279 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1126\/science.1068819","volume":"295","author":"Y Shen","year":"2002","unstructured":"Shen, Y. et al. Adaptive immune response of V gamma 2V delta 2(+) T cells during mycobacterial infections. Science 295, 2255\u20132258 (2002).","journal-title":"Science"},{"key":"BFnm1221_CR14","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1073\/pnas.0403787101","volume":"101","author":"K Fischer","year":"2004","unstructured":"Fischer, K. et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA 101, 10685\u201310690 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/path.1628","volume":"204","author":"T Ulrichs","year":"2004","unstructured":"Ulrichs, T. et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol. 204, 217\u2013228 (2004).","journal-title":"J. Pathol."},{"key":"BFnm1221_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/35095558","volume":"1","author":"SHE Kaufmann","year":"2001","unstructured":"Kaufmann, S.H.E. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20\u201330 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnm1221_CR17","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","volume":"178","author":"AM Cooper","year":"1993","unstructured":"Cooper, A.M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243\u20132247 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR18","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","volume":"178","author":"JL Flynn","year":"1993","unstructured":"Flynn, J.L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249\u20132254 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932\u20131939 (1999).","journal-title":"Lancet"},{"key":"BFnm1221_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1521-6616(03)00210-9","volume":"110","author":"J Chan","year":"2004","unstructured":"Chan, J. & Flynn, J. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110, 2\u201312 (2004).","journal-title":"Clin. Immunol."},{"key":"BFnm1221_CR21","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1128\/JB.184.24.6760-6767.2002","volume":"184","author":"C Boon","year":"2002","unstructured":"Boon, C. & Dick, T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J. Bacteriol. 184, 6760\u20136767 (2002).","journal-title":"J. Bacteriol."},{"key":"BFnm1221_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.20030205","volume":"198","author":"MI Voskuil","year":"2003","unstructured":"Voskuil, M.I. et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705\u2013713 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR23","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1073\/pnas.121172498","volume":"98","author":"DR Sherman","year":"2001","unstructured":"Sherman, D.R. et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc. Natl. Acad. Sci. USA 98, 7534\u20137539 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0966-842X(01)02277-6","volume":"10","author":"PJ Bifani","year":"2002","unstructured":"Bifani, P.J., Mathema, B., Kurepina, N.E. & Kreiswirth, B.N. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 10, 45\u201352 (2002).","journal-title":"Trends Microbiol."},{"key":"BFnm1221_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3201\/eid0805.020002","volume":"8","author":"JR Glynn","year":"2002","unstructured":"Glynn, J.R., Whiteley, J., Bifani, P.J., Kremer, K. & van Soolingen, D. Worldwide occurrence of Beijing\/W strains of Mycobacterium tuberculosis: a systematic review. Emerg. Infect. Dis. 8, 843\u2013849 (2002).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnm1221_CR26","first-page":"426","volume":"160","author":"O Naegeli","year":"1900","unstructured":"Naegeli, O. Ueber H\u00e4ufigkeit, Localisation und Ausheilung der Tuberculose. Archiv f\u00fcr pathologische Anatomie und Physiologie und f\u00fcr klinische Medizin 160, 426\u2013472 (1900).","journal-title":"Archiv f\u00fcr pathologische Anatomie und Physiologie und f\u00fcr klinische Medizin"},{"key":"BFnm1221_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev.immunol.20.081501.125851","volume":"20","author":"J-L Casanova","year":"2002","unstructured":"Casanova, J.-L. & Abel, L. Genetic dissection of immunity to Mycobacteria: the human model. Annu. Rev. Immunol. 20, 581\u2013620 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnm1221_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/35103577","volume":"2","author":"GS Cooke","year":"2001","unstructured":"Cooke, G.S. & Hill, A.V. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2, 967\u2013977 (2001).","journal-title":"Nat. Rev. Genet."},{"key":"BFnm1221_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nrmicro1046","volume":"2","author":"UE Schaible","year":"2004","unstructured":"Schaible, U.E. & Kaufmann, S.H. Iron and microbial infection. Nat. Rev. Microbiol. 2, 946\u2013953 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnm1221_CR30","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1056\/NEJM199910143411602","volume":"341","author":"A Van Rie","year":"1999","unstructured":"Van Rie, A. et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174\u20131179 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnm1221_CR31","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ni981","volume":"4","author":"SM Hingley-Wilson","year":"2003","unstructured":"Hingley-Wilson, S.M., Sambandamurthy, V.K. & Jacobs, W.R., Jr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat. Immunol. 4, 949\u2013955 (2003).","journal-title":"Nat. Immunol."},{"key":"BFnm1221_CR32","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.1093\/clinids\/11.Supplement_2.S353","volume":"11","author":"PEM Fine","year":"1989","unstructured":"Fine, P.E.M. The BCG story - lessons from the past and implications for the future. Rev. Infect. Dis. 11, S353\u2013S359 (1989).","journal-title":"Rev. Infect. Dis."},{"key":"BFnm1221_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz, G.A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271, 698\u2013702 (1994).","journal-title":"JAMA"},{"key":"BFnm1221_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1389201033377931","volume":"4","author":"LM Okkels","year":"2003","unstructured":"Okkels, L.M., Doherty, T.M. & Andersen, P. Selecting the components for a safe and efficient tuberculosis subunit vaccine\u2014recent progress and post-genomic insights. Curr. Pharm. Biotechnol. 4, 69\u201383 (2003).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"BFnm1221_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm0896-893","volume":"2","author":"K Huygen","year":"1996","unstructured":"Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2, 893\u2013898 (1996).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR36","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","volume":"69","author":"AW Olsen","year":"2001","unstructured":"Olsen, A.W., van Pinxteren, L.A.H., Okkels, L.M., Rasmussen, P.B. & Andersen, P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69, 2773\u20132778 (2001).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR37","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/IAI.72.11.6471-6479.2004","volume":"72","author":"HJ Mollenkopf","year":"2004","unstructured":"Mollenkopf, H.J. et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72, 6471\u20136479 (2004).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/3527601449","volume-title":"Novel Vaccination Strategies","author":"SHE Kaufmann","year":"2004","unstructured":"Kaufmann, S.H.E. (ed.) Novel Vaccination Strategies (John Wiley & Sons, Weinheim, 2004)."},{"key":"BFnm1221_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/3527601449.ch8","volume-title":"Novel Vaccination Strategies","author":"DT O'Hagan","year":"2004","unstructured":"O'Hagan, D.T. & Singh, M. Microparticles as vaccine adjuvants and delivery systems. in Novel Vaccination Strategies (ed. Kaufmann, S.H.E.) 147\u2013172 (John Wiley & Sons, Weinheim, 2004)."},{"key":"BFnm1221_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nm1128","volume":"10","author":"H McShane","year":"2004","unstructured":"McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240\u20131244 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/IAI.69.2.681-686.2001","volume":"69","author":"H McShane","year":"2001","unstructured":"McShane, H., Brookes, R., Gilbert, S.C. & Hill, A.V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69, 681\u2013686 (2001).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR42","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","volume":"172","author":"YA Skeiky","year":"2004","unstructured":"Skeiky, Y.A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618\u20137628 (2004).","journal-title":"J. Immunol."},{"key":"BFnm1221_CR43","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","volume":"72","author":"L Brandt","year":"2004","unstructured":"Brandt, L. et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72, 6622\u20136632 (2004).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm0396-334","volume":"2","author":"I Guleria","year":"1996","unstructured":"Guleria, I. et al. Auxotrophic vaccines for tuberculosis. Nat. Med. 2, 334\u2013337 (1996).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR45","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1128\/IAI.69.2.1442-1150.2001","volume":"69","author":"DA Smith","year":"2001","unstructured":"Smith, D.A., Parish, T., Stoker, N.G. & Bancroft, G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69, 1142\u20131150 (2001).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2958.2001.02500.x","volume":"41","author":"E Perez","year":"2001","unstructured":"Perez, E. et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol. Microbiol. 41, 179\u2013187 (2001).","journal-title":"Mol. Microbiol."},{"key":"BFnm1221_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/47042","volume":"402","author":"JS Cox","year":"1999","unstructured":"Cox, J.S., Chen, B., McNeil, M. & Jacobs, W.R. Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79\u201383 (1999).","journal-title":"Nature"},{"key":"BFnm1221_CR48","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/35021074","volume":"406","author":"JD McKinney","year":"2000","unstructured":"McKinney, J.D. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735\u2013738 (2000).","journal-title":"Nature"},{"key":"BFnm1221_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/35084083","volume":"412","author":"K Pethe","year":"2001","unstructured":"Pethe, K. et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412, 190\u2013194 (2001).","journal-title":"Nature"},{"key":"BFnm1221_CR50","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/IAI.72.9.5315-5321.2004","volume":"72","author":"KB Hisert","year":"2004","unstructured":"Hisert, K.B. et al. Identification of Mycobacterium tuberculosis counterimmune (cim) mutants in immunodeficient mice by differential screening. Infect. Immun. 72, 5315\u20135321 (2004).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"MA Behr","year":"1999","unstructured":"Behr, M.A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520\u20131523 (1999).","journal-title":"Science"},{"key":"BFnm1221_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym, A.S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9, 533\u2013539 (2003).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR53","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1073\/pnas.250480397","volume":"97","author":"MA Horwitz","year":"2000","unstructured":"Horwitz, M.A., Harth, G., Dillon, B.J. & Maslesa-Galic, S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97, 13853\u201313858 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1073\/pnas.93.2.934","volume":"93","author":"PJ Murray","year":"1996","unstructured":"Murray, P.J., Aldovini, A. & Young, R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA 93, 934\u2013939 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1046\/j.1365-2249.2000.01100.x","volume":"119","author":"A Wangoo","year":"2000","unstructured":"Wangoo, A. et al. Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin. Exp. Immunol. 119, 92\u201398 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm1221_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","volume":"123","author":"Y Luo","year":"2001","unstructured":"Luo, Y., Chen, X., Han, R. & O'Donnell, M.A. Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin. Exp. Immunol. 123, 264\u2013270 (2001).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm1221_CR57","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1073\/pnas.95.9.5299","volume":"95","author":"J Hess","year":"1998","unstructured":"Hess, J. et al. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95, 5299\u20135304 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR58","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1128\/iai.60.4.1263-1267.1992","volume":"60","author":"DA Portnoy","year":"1992","unstructured":"Portnoy, D.A., Chakraborty, T., Goebel, W. & Cossart, P. Molecular determinants of Listeria monocytogenes pathogenesis. Infect. Immun. 60, 1263\u20131267 (1992).","journal-title":"Infect. Immun."},{"key":"BFnm1221_CR59","unstructured":"Kaufmann, S.H.E. & Nasser, A. Improved protection by recombinant BCG. Microbes Infect. (in the press)."},{"key":"BFnm1221_CR60","unstructured":"Kamath, A.T. et al. New live mycobacterial vaccines: The Geneva consensus on essential steps towards clinical development. Vaccine in the press."},{"key":"BFnm1221_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1570162043351327","volume":"2","author":"I Markovic","year":"2004","unstructured":"Markovic, I. & Clouse, K.A. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr. HIV Res. 2, 223\u2013234 (2004).","journal-title":"Curr. HIV Res."},{"key":"BFnm1221_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrmicro772","volume":"1","author":"V Simon","year":"2003","unstructured":"Simon, V. & Ho, D.D. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1, 181\u2013190 (2003).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnm1221_CR63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev.immunol.15.1.271","volume":"15","author":"AJ McMichael","year":"1997","unstructured":"McMichael, A.J. & Phillips, R.E. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15, 271\u2013296 (1997).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnm1221_CR64","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1084\/jem.20031598","volume":"198","author":"SA Younes","year":"2003","unstructured":"Younes, S.A. et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198, 1909\u20131922 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/417095a","volume":"417","author":"DC Douek","year":"2002","unstructured":"Douek, D.C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95\u201398 (2002).","journal-title":"Nature"},{"key":"BFnm1221_CR66","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.med.53.082901.104024","volume":"53","author":"JN Blankson","year":"2002","unstructured":"Blankson, J.N., Persaud, D. & Siliciano, R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557\u2013593 (2002).","journal-title":"Annu. Rev. Med."},{"key":"BFnm1221_CR67","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.1470917","volume":"258","author":"MD Daniel","year":"1992","unstructured":"Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938\u20131941 (1992).","journal-title":"Science"},{"key":"BFnm1221_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nm0304-221","volume":"10","author":"RC Desrosiers","year":"2004","unstructured":"Desrosiers, R.C. Prospects for an AIDS vaccine. Nat. Med. 10, 221\u2013223 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR69","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1172\/JCI4314","volume":"102","author":"SL Rowland-Jones","year":"1998","unstructured":"Rowland-Jones, S.L. et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758\u20131765 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnm1221_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1172\/JCI10714","volume":"107","author":"R Kaul","year":"2001","unstructured":"Kaul, R. et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 107, 341\u2013349 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnm1221_CR71","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nature01200","volume":"420","author":"M Altfeld","year":"2002","unstructured":"Altfeld, M. et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420, 434\u2013439 (2002).","journal-title":"Nature"},{"key":"BFnm1221_CR72","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1126\/science.288.5472.1789","volume":"288","author":"B Korber","year":"2000","unstructured":"Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789\u20131796 (2000).","journal-title":"Science"},{"key":"BFnm1221_CR73","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20041251","volume":"200","author":"JK Lee","year":"2004","unstructured":"Lee, J.K. et al. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200, 1455\u20131466 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nm0304-229","volume":"10","author":"JD Altman","year":"2004","unstructured":"Altman, J.D. & Feinberg, M.B. HIV escape: there and back again. Nat. Med. 10, 229\u2013230 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR75","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1126\/science.1093137","volume":"303","author":"CA Derdeyn","year":"2004","unstructured":"Derdeyn, C.A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019\u20132022 (2004).","journal-title":"Science"},{"key":"BFnm1221_CR76","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri1417","volume":"4","author":"PJ Goulder","year":"2004","unstructured":"Goulder, P.J. & Watkins, D.I. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4, 630\u2013640 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnm1221_CR77","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1073\/pnas.0630530100","volume":"100","author":"DD Richman","year":"2003","unstructured":"Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144\u20134149 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR78","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1069660","volume":"296","author":"CB Moore","year":"2002","unstructured":"Moore, C.B. et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439\u20131443 (2002).","journal-title":"Science"},{"key":"BFnm1221_CR79","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/415335a","volume":"415","author":"DH Barouch","year":"2002","unstructured":"Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335\u2013339 (2002).","journal-title":"Nature"},{"key":"BFnm1221_CR80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nm998","volume":"10","author":"TC Friedrich","year":"2004","unstructured":"Friedrich, T.C. et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 10, 275\u2013281 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR81","doi-asserted-by":"publisher","first-page":"15131","DOI":"10.1073\/pnas.2436476100","volume":"100","author":"Y Nishimura","year":"2003","unstructured":"Nishimura, Y. et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 100, 15131\u201315136 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm1221_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.1058915","volume":"292","author":"RR Amara","year":"2001","unstructured":"Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine. Science 292, 69\u201374 (2001).","journal-title":"Science"},{"key":"BFnm1221_CR83","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.290.5491.486","volume":"290","author":"DH Barouch","year":"2000","unstructured":"Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486\u2013492 (2000).","journal-title":"Science"},{"key":"BFnm1221_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","volume":"415","author":"JW Shiver","year":"2002","unstructured":"Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331\u2013335 (2002).","journal-title":"Nature"},{"key":"BFnm1221_CR85","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/00002030-200307040-00012","volume":"17","author":"AS Alabi","year":"2003","unstructured":"Alabi, A.S. et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 17, 1513\u20131520 (2003).","journal-title":"AIDS"},{"key":"BFnm1221_CR86","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/ni0304-233","volume":"5","author":"DR Burton","year":"2004","unstructured":"Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233\u2013236 (2004).","journal-title":"Nat. Immunol."},{"key":"BFnm1221_CR87","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/31514","volume":"393","author":"R Wyatt","year":"1998","unstructured":"Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705\u2013711 (1998).","journal-title":"Nature"},{"key":"BFnm1221_CR88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/351479a0","volume":"351","author":"A Aldovini","year":"1991","unstructured":"Aldovini, A. & Young, R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351, 479\u2013482 (1991).","journal-title":"Nature"},{"key":"BFnm1221_CR89","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nm0598supp-515","volume":"4","author":"MA Liu","year":"1998","unstructured":"Liu, M.A. Vaccine developments. Nat. Med. 4, 515\u2013519 (1998).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","volume":"12","author":"G Sutter","year":"1994","unstructured":"Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R. & Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032\u20131040 (1994).","journal-title":"Vaccine"},{"key":"BFnm1221_CR91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1086\/346054","volume":"187","author":"XL Huang","year":"2003","unstructured":"Huang, X.L. et al. Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J. Infect. Dis. 187, 315\u2013319 (2003).","journal-title":"J. Infect. Dis."},{"key":"BFnm1221_CR92","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0264-410X(02)00074-9","volume":"20","author":"GJ Nabel","year":"2002","unstructured":"Nabel, G.J. HIV vaccine strategies. Vaccine 20, 1945\u20131947 (2002).","journal-title":"Vaccine"},{"key":"BFnm1221_CR93","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1086\/315199","volume":"181","author":"RR MacGregor","year":"2000","unstructured":"MacGregor, R.R., Boyer, J.D., Ciccarelli, R.B., Ginsberg, R.S. & Weiner, D.B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env\/rev vaccine in HIV-infected recipients: follow-up data. J. Infect. Dis. 181, 406 (2000).","journal-title":"J. Infect. Dis."},{"key":"BFnm1221_CR94","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nm881","volume":"9","author":"SJ McConkey","year":"2003","unstructured":"McConkey, S.J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729\u2013735 (2003).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1399-0039.2004.00270.x","volume":"64","author":"R Paris","year":"2004","unstructured":"Paris, R. et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 64, 251\u2013256 (2004).","journal-title":"Tissue Antigens"},{"key":"BFnm1221_CR96","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0264-410X(97)00226-0","volume":"16","author":"T Hanke","year":"1998","unstructured":"Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime\/MVA boost vaccination regime. Vaccine 16, 439\u2013445 (1998).","journal-title":"Vaccine"},{"key":"BFnm1221_CR97","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nm0498-397","volume":"4","author":"J Schneider","year":"1998","unstructured":"Schneider, J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397\u2013402 (1998).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR98","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ni1105","volume":"5","author":"JC Sun","year":"2004","unstructured":"Sun, J.C., Williams, M.A. & Bevan, M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5, 927\u2013933 (2004).","journal-title":"Nat. Immunol."},{"key":"BFnm1221_CR99","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337\u2013339 (2003).","journal-title":"Science"},{"key":"BFnm1221_CR100","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/30989","volume":"393","author":"JP Ridge","year":"1998","unstructured":"Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474\u2013478 (1998).","journal-title":"Nature"},{"key":"BFnm1221_CR101","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.4049\/jimmunol.168.7.3477","volume":"168","author":"H Liu","year":"2002","unstructured":"Liu, H., Andreansky, S., Diaz, G., Hogg, T. & Doherty, P.C. Reduced functional capacity of CD8+ T cells expanded by post-exposure vaccination of gamma-herpesvirus-infected CD4-deficient mice. J. Immunol. 168, 3477\u20133483 (2002).","journal-title":"J. Immunol."},{"key":"BFnm1221_CR102","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/eji.1830260915","volume":"26","author":"JM Brewer","year":"1996","unstructured":"Brewer, J.M., Conacher, M., Satoskar, A., Bluethmann, H. & Alexander, J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 26, 2062\u20132066 (1996).","journal-title":"Eur. J. Immunol."},{"key":"BFnm1221_CR103","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.1096378","volume":"304","author":"CC Norbury","year":"2004","unstructured":"Norbury, C.C. et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304, 1318\u20131321 (2004).","journal-title":"Science"},{"key":"BFnm1221_CR104","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1126\/science.1096268","volume":"304","author":"MC Wolkers","year":"2004","unstructured":"Wolkers, M.C., Brouwenstijn, N., Bakker, A.H., Toebes, M. & Schumacher, T.N. Antigen bias in T cell cross-priming. Science 304, 1314\u20131317 (2004).","journal-title":"Science"},{"key":"BFnm1221_CR105","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/ni1003-939","volume":"4","author":"AS Beignon","year":"2003","unstructured":"Beignon, A.S., Skoberne, M. & Bhardwaj, N. Type I interferons promote cross-priming: more functions for old cytokines. Nat. Immunol. 4, 939\u2013941 (2003).","journal-title":"Nat. Immunol."},{"key":"BFnm1221_CR106","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni978","volume":"4","author":"A Le Bon","year":"2003","unstructured":"Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009\u20131015 (2003).","journal-title":"Nat. Immunol."},{"key":"BFnm1221_CR107","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","volume":"86","author":"R Liu","year":"1996","unstructured":"Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367\u2013377 (1996).","journal-title":"Cell"},{"issue":"Suppl 1","key":"BFnm1221_CR108","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/00002030-200102001-00013","volume":"15","author":"AT Haase","year":"2001","unstructured":"Haase, A.T. The pathogenesis of sexual mucosal transmission and early stages of infection: obstacles and a narrow window of opportunity for prevention. AIDS 15 Suppl 1, S10\u2013S11 (2001).","journal-title":"AIDS"},{"key":"BFnm1221_CR109","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1084\/jem.20040874","volume":"200","author":"JM Brenchley","year":"2004","unstructured":"Brenchley, J.M. et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749\u2013759 (2004).","journal-title":"J. Exp. Med."},{"key":"BFnm1221_CR110","first-page":"561","volume-title":"Tuberculosis and the Tubercle Bacillus","author":"IM Orme","year":"2005","unstructured":"Orme, I.M. & Izzo, A.A. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T., Eisenach, K.D., McMurray, D.N. & Jacobs, W.R., Jr.) 561\u2013571 (ASM Press, Washington, DC, 2005)."},{"key":"BFnm1221_CR111","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","volume":"4","author":"M Pai","year":"2004","unstructured":"Pai, M., Riley, L.W. & Colford, J.M. Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761\u2013776 (2004).","journal-title":"Lancet Infect. Dis."},{"key":"BFnm1221_CR112","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1006\/viro.2002.1379","volume":"296","author":"RJ Stebbings","year":"2002","unstructured":"Stebbings, R.J. et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. Virology 296, 338\u2013353 (2002).","journal-title":"Virology"},{"key":"BFnm1221_CR113","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1128\/JVI.78.6.3140-3144.2004","volume":"78","author":"AB McDermott","year":"2004","unstructured":"McDermott, A.B. et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78, 3140\u20133144 (2004).","journal-title":"J. Virol."},{"key":"BFnm1221_CR114","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/80481","volume":"6","author":"Z Hel","year":"2000","unstructured":"Hel, Z. et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6, 1140\u20131146 (2000).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR115","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1147","volume":"10","author":"W Lu","year":"2004","unstructured":"Lu, W., Arraes, L.C., Ferreira, W.T. & Andrieu, J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10, 1359\u20131365 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR116","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.4049\/jimmunol.169.9.5347","volume":"169","author":"E Tryniszewska","year":"2002","unstructured":"Tryniszewska, E. et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169, 5347\u20135357 (2002).","journal-title":"J. Immunol."},{"key":"BFnm1221_CR117","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JVI.73.1.797-800.1999","volume":"73","author":"GS Ogg","year":"1999","unstructured":"Ogg, G.S. et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797\u2013800 (1999).","journal-title":"J. Virol."},{"key":"BFnm1221_CR118","volume-title":"Strong Medicine: Creating Incentives For Pharmaceutical Research on Neglected Diseases","author":"M Kremer","year":"2004","unstructured":"Kremer, M. & Glennerster, R. Strong Medicine: Creating Incentives For Pharmaceutical Research on Neglected Diseases (Princeton University Press, Princeton, Oxford, 2004)."},{"key":"BFnm1221_CR119","unstructured":"World Health Organization. Global Atlas of infectious diseases. http:\/\/globalatlas.who.int\/. (World Health Organization, Geneva, 2004)."},{"key":"BFnm1221_CR120","unstructured":"UNAIDS. 2004 Report on the global AIDS epidemic. 2004. Geneva."},{"key":"BFnm1221_CR121","unstructured":"World Health Organization. The World Health Report 2004 - Changing History. 2004. Switzerland. (World Health Organization, Geneva, 2004)."},{"key":"BFnm1221_CR122","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0140-6736(02)09095-5","volume":"359","author":"EL Corbett","year":"2002","unstructured":"Corbett, E.L. et al. HIV-1\/AIDS and the control of other infectious diseases in Africa. Lancet 359, 2177\u20132187 (2002).","journal-title":"Lancet"},{"key":"BFnm1221_CR123","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nm1090","volume":"10","author":"S Temmerman","year":"2004","unstructured":"Temmerman, S. et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat. Med. 10, 935\u2013941 (2004).","journal-title":"Nat. Med."},{"key":"BFnm1221_CR124","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/22326","volume":"400","author":"DB Lowrie","year":"1999","unstructured":"Lowrie, D.B. et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269\u2013271 (1999).","journal-title":"Nature"},{"key":"BFnm1221_CR125","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1128\/IAI.69.4.2714-2717.2001","volume":"69","author":"JV Brooks","year":"2001","unstructured":"Brooks, J.V., Frank, A.A., Keen, M.A., Bellisle, J.T. & Orme, I.M. Boosting vaccine for tuberculosis. Infect. Immun. 69, 2714\u20132717 (2001).","journal-title":"Infect. Immun."}],"updated-by":[{"DOI":"10.1038\/nm0505-578a","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm1221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm1221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm1221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:07:26Z","timestamp":1744290446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":125,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["BFnm1221"],"URL":"https:\/\/doi.org\/10.1038\/nm1221","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nm0505-578a","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"5 April 2005","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}